Güvenç-Bayram, GökçenYalçın, Murat2024-06-052024-06-052021-05-230304-3940https://doi.org/10.1016/j.neulet.2021.135961https://hdl.handle.net/11452/41778That nesfatin-1 is a neuromodulatory peptide for the cardiovascular system is well documented. Several central receptors have been shown to mediate the cardiovascular effects of nesfatin-1. Immunohistochemistry and Western blot studies showed that nesfatin-1 activated the expression of the central cyclooxygenase (COX) -1, -2 and lipoxygenase (LOX). In addition, microdialysis study showed that nesfatin-1 increased the release of total prostaglandins and leukotrienes from the hypothalamus. The present study investigated whether the central COX and LOX enzymes have a direct mediating role in the MAP and HR responses of nesfatin-1.Intracerebroventricularly administered nesfatin-1 produced dose-dependent pressor and phasic HR responses in normotensive conscious rats Sprague Dawley. Central pretreatment with a COX1/2 inhibitor, ibuprofen, completely blocked the nesfatin-1-induced responses. However, central pretreatment with a nonselective LOX inhibitor, nordihydroguaiaretic acid, partially attenuated the cardiovascular responses induced by nesfatin-1.The results suggest that centrally administered nesfatin-1 activates the central enzymes COX and LOX, which may be involved in the cardiovascular responses as a novel central mechanism for nesfatin-1.eninfo:eu-repo/semantics/openAccessHemorrhaged hypotensive ratsCentral histaminergic systemBrain thromboxane a(2)Arachidonic-acidNitric-oxideFood-intakeInvolvementPressorMelittinReceptorNesfatin-1IntracerebroventricularCyclooxygenaseLipoxygenaseMean arterial blood pressureHeart rateScience & technologyLife sciences & biomedicineNeurosciencesNeurosciences & neurologyArticle00065565750000375610.1016/j.neulet.2021.135961